背景:这项研究旨在评估海马回避全脑放疗同时结合增强(HA-WBRT-SIB)治疗脑转移(BM)的有效性以及霍普金斯言语学习测试的有效性-修订版(HVLT-R)(中文版)在中国肺癌患者中的应用。
方法:纳入本中心接受HA-WBRT-SIB的BM肺癌患者。脑磁共振成像,HVLT学习总分,放疗前和放疗后1、3、6和12个月评估副作用。本研究分析了总体生存率,无进展生存率,以及HVLT-R即时召回分数的变化。
结果:2016年1月至2020年1月共纳入40例患者。中位随访时间为14.2个月。中位生存期,无进展生存期,所有患者颅内无进展生存期为14.8个月,6.7个月和14.8个月,分别。多因素分析显示男性和新诊断的IV期疾病与低总生存期和无进展生存期相关。分别。基线和放疗后1、3和6个月的HVLT-R评分分别为21.94±2.99、20.88±3.12、20.03±3.14和19.78±2.98。放疗后6个月的HVLT-R评分与基线相比下降约9.8%。在整个队列中没有发生3级毒性。
结论:HA-WBRT-SIB治疗中国肺癌BM具有有效性和认知功能。
背景:这项研究于2月24日在ClinicalTrials.gov上进行了回顾性注册,2024.ClinicalTrials.govID是NCT06289023。
BACKGROUND: This
study aimed to evaluate the efficiency of hippocampal avoidance whole-brain radiotherapy with a simultaneous integrated boost (HA-WBRT-SIB) treating brain metastases (BM) and utility of the Hopkins Verbal Learning Test-Revised (HVLT-R) (Chinese version) in Chinese lung cancer patients.
METHODS: Lung cancer patients with BM undergone HA-WBRT-SIB at our center were enrolled. Brain magnetic resonance imaging, The HVLT total learning score, and side effects were evaluated before radiotherapy and 1, 3, 6, and 12 months after radiotherapy. This
study analyzed the overall survival rate, progression-free survival rate, and changes in HVLT-R immediate recall scores.
RESULTS: Forty patients were enrolled between Jan 2016 and Jan 2020. The median follow-up time was 14.2 months. The median survival, progression-free survival, and intracranial progression-free survival of all patients were 14.8 months, 6.7 months and 14.8 months, respectively. Multivariate analysis indicated that male sex and newly diagnosed stage IV disease were associated with poor overall survival and progression-free survival, respectively. HVLT-R scores at baseline and 1, 3, and 6 months after radiotherapy were 21.94 ± 2.99, 20.88 ± 3.12, 20.03 ± 3.14, and 19.78 ± 2.98, respectively. The HVLT-R scores at 6 months after radiotherapy decreased by approximately 9.8% compared with those at baseline. No grade 3 toxicities occurred in the entire cohort.
CONCLUSIONS: HA-WBRT-SIB is of efficiency and cognitive-conserving in treating Chinese lung cancer BM.
BACKGROUND: This
study was retrospectively registered on ClinicalTrials.gov in 24th Feb, 2024. The ClinicalTrials.gov ID is NCT06289023.